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ABSTRACT
The transcription factor RUNX1 (AML1) is an
important regulator of haematopoiesis, and an
important fusion partner in leukaemic translo-
cations. High-affinity DNA binding by RUNX1
requires the interaction of the RUNX1 Runt-
Homology-Domain (RHD) with the core-binding
factor b protein (CBFb). To generate novel reagents
for in vitro and in vivo studies of RUNX1 function, we
have selected high-affinity RNA aptamers against a
recombinant RHD–CBFb complex. Selection yielded
two sequence families, each dominated by a single
consensus sequence. Aptamers from each family
disrupt DNA binding by the RUNX1 protein in vitro
and compete with sequence-specific dsDNA
binding. Minimal, high-affinity (100–160 nM) active
aptamer fragments 28 and 30nts in length,
consisting of simple short stem-loop structures,
were then identified. These bind to the RHD
subunit and disrupt its interaction with CBFb,
which is consistent with reduced DNA affinity
in the presence of aptamer. These aptamers
represent new reagents that target a novel surface
on the RHD required to stabilize the recombinant
RHD–CBFb complex and thus will further aid
exploring the functions of this key transcription
factor.
INTRODUCTION
The transcription factor RUNX1 (AML1) is one of the
most important regulators of haematopoiesis and is
involved in the regulation of transcription of a range of
blood cell-specific genes. It is expressed at high levels in
haematopoietic stem cells and cells committed to all blood
cell lineages, including myeloid precursors (1,2). Analysis
of RUNX1-deficient mice showed that they do not
generate definitive haematopoietic cells and the embryos
die at around day 12 of development (3). The region
most conserved in RUNX1 proteins is the 128 amino
acid Runt-Homology-Domain (RHD), which is located
at the N-terminus of the protein and is responsible for
binding to the consensus DNA sequence PyGPyGGTPy
(Py=pyrimidine) (4,5). The RHD allows RUNX1 to
heterodimerize with the core-binding factor beta (CBFb)
protein (4) to form a complex that binds more tightly to its
DNA target (6). This interaction is vital for RUNX1
function, as shown by the finding that mice carrying
a targeted mutation of the CBFb gene display the
same phenotype as RUNX1-null mice (6). RUNX1
also interacts with a number of other proteins, including
other transcription factors, as well as co-activators
and co-repressors. The latter includes histone
acetyltransferases, such as CBP, p300 and MOZ and
repressor molecules such as Sin3A (7–9), for review see
(1). These proteins interact with a number of different
domains C-terminal of the RHD. RUNX1 can thus
function both as an activator and a repressor and these
activities are context dependent.
In addition to its role in the regulation of normal
haematopoiesis, the RUNX1 gene is an important
proto-oncogene. Chromosomal translocations affecting
this gene are a recurring feature in acute leukaemias
with t(8;21), t(16;21) and t(12;21) being three of the
most frequently observed (1,8). Both of these trans-
locations retain the DNA-binding domain of RUNX1
and are therefore still able to bind to DNA but have
lost the ability to be properly regulated, leading to a
reprogramming of the chromatin structure of target
*To whom correspondence should be addressed. Tel: +44 113 343 8525; Fax: +44 113 343 8502; Email: c.bonifer@leeds.ac.uk
Correspondence may also be addressed to Peter G. Stockley. Tel: +44 113 343 3092; Fax: +44 113 343 7897; Email: stockley@bmb.leeds.ac.uk
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
6818–6830 Nucleic Acids Research, 2009, Vol. 37, No. 20 Published online 9 September 2009
doi:10.1093/nar/gkp728
 The Author(s) 2009. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
genes and the deregulation of gene expression (10–12).
The fusion proteins also maintain the capacity to
interact with CBFb and this interaction contributes to
their activities (13). The interactions of the RHD
domain of RUNX1 with DNA and CBFb are therefore
potential targets for therapeutic intervention.
A novel, promising class of compounds with potential
as both research tools and therapeutics are aptamers-
structured polynucleotide sequences that can be isolated
by in vitro selection from randomized oligonucleotide
libraries (14–17). Aptamers have distinct advantages
over antibodies as potential therapeutics and diagnostics
as they are significantly smaller, can be isolated rapidly
in vitro and modified to include chromophores, fluoro-
phores, radiolabels or novel chemical groups. In
addition, aptamers do not carry the secondary functional
signals of antibodies, such as complement fixation, and
do not elicit a significant immune response (17,18). The
first aptamer-based drugs are beginning to appear in the
clinic (19) [reviewed in (20)].
Besides their value as novel therapeutic agents,
aptamers can be selected against defined protein target
surfaces, facilitating the study of inter-molecular interac-
tions and their sites of action. Indeed, RNA aptamers
have been generated against a number of transcription
factors and shown to interfere with a range of molecular
interactions both in vitro and in vivo (21–25). In a similar
effort, we have isolated high-affinity aptamers that alter
the affinity of RUNX1 for DNA and investigated their
effects on DNA binding and CBF complex formation.
Analysis of selected aptamers revealed two dominant
sequence families, each of which disrupts the binding of
RUNX1 proteins to DNA. We have identified minimal
short stem-loop sequences from these consensus sequences
which retain binding activity (Kds 100–160 nM). These
short structures compete with DNA binding by the RHD–
CBFb complex by binding the RHD subunit disrupting
the interaction with CBFb. This competition between
DNA- and RNA-binding activities raises the possibility
that RNA binding might be involved in regulating the
function of this complex in vivo.
MATERIALS AND METHODS
Biotinylation and immobilization of RHD–CBFb
The recombinant RHD–CBFb protein complex was
partially biotinylated with 20-fold molar excess of
EZ-Link Sulfo-NHS-LC-LC-biotin (Pierce), according
to the manufacturer’s protocol. The biotinylated samples
were then immobilized on 1 mm MyOneTM streptavidin-
coated Dynabeads (Invitrogen), according to the
manufacturer’s protocol.
In vitro transcription
The initial dsDNA SELEX library consists of 1015
sequences, each containing an N50 random region,
flanked by two fixed primer regions; one of which
carries the T7 RNA polymerase promoter. All RNAs
were prepared in 50 ml reactions containing a final
concentration of 40mM HEPES NaOH pH 7.6, 26mM
MgCl2, 2mM spermidine, 40mM DTT, 2.5mM each
ATP, GTP, 20-fluoro-UTP, 20-fluoro-CTP, 5 ml dsDNA
template, 100U T7 RNA polymerase, 0.5U Yeast
Inorganic Pyrophosphatase (Sigma). This was thoroughly
mixed then incubated at 37C for 3 h. To improve RNA
yields T7 R&DNATM polymerase (Epicentre Biotech-
nologies) was used in all transcription reactions containing
20-fluoro-modified nucleotides. Template DNA was then
removed by addition of 6 ml DNase 1 buffer (to final
concentration of 40mM Tris–HCl pH 8, 10mM MgSO4,
1mM CaCl2) and 4U RQ1 DNase (Promega), then
incubating at 37C for 20min. The DNase was inactivated
by heating the reaction to 65C for 5min. The RNA was
then purified using RNACleanTM resin following the
manufacturer’s protocol (Agencourt).
In vitro selection
The purified RNA pool was counter selected in every
round by pre-incubation with 200 mg of underivatized
MyOneTM Dynabeads (Invitrogen) in 100 ml selection
buffer (10mM HEPES NaOH pH 7.4, 100mM NaCl) at
37C for 5min. The beads were then separated and the
unbound RNA was removed and added to 200 mg
Dynabeads, saturated with biotinylated RHD–CBFb.
After incubation at 37C for 20min, the beads were
separated and gently washed six times to remove any
unbound RNA. The beads were then suspended in 50 ml
of selection buffer and incubated (37C, 5min) to allow
any weakly bound RNA to dissociate. The beads were
again separated and unbound material was removed.
Aptamers were then eluted by heating the beads to 95C
for 10min in 30 ml RNase-free water. Eluted RNAs were
reverse transcribed and polymerase chain reaction (PCR)
amplified as described below. The stringency of selection
was gradually increased by reducing the amount of RHD–
CBFb beads from 300 to 50 mg of total protein, reducing
the incubation time (from 20 to 5min) and increasing the
dissociation time (from 5 to 20min).
RT–PCR
Twenty microlitre RT–PCR mix was added to the eluted
RNA to give a final concentration of 50mM Tris–HCl pH
8.5, 30mM KCl, 8mM MgCl2, 2 mM reverse primer (50-G
GGGTCATAGTATCCTAGTTG-30), 1mM each dNTP,
20U TranscriptorTM reverse transcriptase (Roche). This
was incubated at 52C for 2 h before adding PCR mix.
PCR amplification was carried out in 70 ml reactions con-
taining 20mM Tris–HCl pH 8.4, 50mM KCl, 1.5mM
MgCl2, 200 mM dNTP mix and 500 nM forward primer
(50-CCCAAGCTTAATACGACTCACTATAGGGAGC
TCCAGAAGATAAATTACAGG-30). Five hundred
nanomolar reverse primer and 2.5U of Taq DNA
polymerase (Invitrogen) were then added before cycling.
This PCR product was used as the template in the
subsequent round of selection. A Biomek 2000 automated
workstation (Beckman Coulter) was used to carry out 10
rounds of in vitro selection.
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RNA/DNA synthesis
RNA for use in EMSAs was transcribed using in vitro
transcription reactions (as described earlier), spiked with
2.5mCiml1 guanosine 50-[a-32P] triphosphate (GE
Healthcare). As in the selections, T7 R&DNATM poly-
merase was used to improve aptamer yields. After
incubation (37C, 3 h) RNA samples were DNase 1
treated and purified by acidified phenol/chloroform
extraction, then ethanol precipitation. Samples were then
run out on a 10% (w/v) denaturing polyacrylamide gel
(19 : 1 bis ratio, 1 TBE, 7M urea) and gel purified by
standard electroelution protocols.
Minimal aptamer sequences were purchased from
Dharmacon and resuspended in nuclease-free water to
a final concentration of 100 mM. 50-fluorescein-labelled
minimal sequences were prepared and purified using
standard protocols (26), whilst their ssDNA equivalents
andRUNX1 probe fragments were purchased fromMWG.
Cell culture and reagents
Kasumi-1 cells (CRL-2724) were obtained from the
American Type Culture Collection (ATCC), VA, USA
and were cultured in RPMI (Sigma-Aldrich, UK)
containing 10% (v/v) foetal calf serum, 10Uml1
penicillin–streptomycin, 2mM L-glutamine (Gibco, UK).
HL60 cells (CCL-240) were from the ATCC and were
cultured in DMEM (Sigma-Aldrich) supplemented with
10% (v/v) foetal calf serum, 10Uml1 penicillin–
streptomycin and 2mM L-glutamine. The goat anti-
RUNX1 antibodies C19 (sc-8564x) and N20 (sc-8564x)
were purchased from Santa Cruz Biotechnology,
CA, USA.
Preparation of nuclear extracts
Cells (2 107) were washed in ice-cold PBS containing
1 complete mini protease inhibitors (Roche) and lysed
in a mild lysis buffer (0.4% (v/v) NP40, 10mM Tris–HCl
pH 7.3, 10mM KCl, 1.5mM MgCl2, 0.5mM PMSF,
0.5mM b-mercaptoethanol) containing 1 complete
mini protease inhibitors. Following centrifugation
for 5min at 16 000g to separate the nuclei from the cyto-
solic fraction, the nuclei were lysed with high-salt buffer
(0.4M NaCl, 20mM HEPES NaOH pH 7.9, 1mM
EDTA, 1mM DTT, 1mM PMSF and 1 complete mini
protease inhibitors).
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSAs) were
performed using either 32P-body-labelled aptamers or
end-labelled, double-stranded (ds) synthetic oligonucleo-
tides harbouring a RUNX1-binding site-(50-TTTCCGCC
CACACAGGCTG-30) (11). Recombinant RHD–CBFb
complex or nuclear extracts were incubated for 15min at
room temperature, together with competitors and/or
antibodies, in 10% (v/v) glycerol, 10mM Tris–HCl pH
7.5, 5mM HEPES NaOH pH 7.9, 50mM KCl, 80mM
NaCl, 1.2mM EDTA, 0.1mgml1 poly-dIdC, 2.2mM
DTT and 300mgml1 BSA. Following this the
32P-labelled aptamer or dsDNA probe was added and
the incubation continued for a further 15min. The
samples were analysed on 5% (w/v) polyacrylamide
(37.5:1 acylamide:bis acrylamide) gels containing 1 TBE.
Aptamer sequencing
To prepare dsDNA with ‘A’-overhangs, PCR were
performed using 0.05U ml1 Taq DNA polymerase
(Promega) in a reaction also containing 1 PCR buffer,
1.25mM MgCl2, 125 mM dNTPs, 500 nM primer 1 and
500 nM primer 2. The PCR products were cloned
into pCR2.1 TA-cloning vector (Invitrogen) as per
manufacturer’s instructions. Individual clones were
sequenced using M13-21 primer (50-TGTAAAACGACG
GCCAGT-30).
Enzymatic secondary structure probing
Individual aptamer clones were selected and transcribed as
described above. 20-F-modified nucleotides were replaced
with regular 20-OH nucleotides. Regular T7 RNA poly-
merase (Roche) was also used. Five microgram of purified
RNA was dephosphorylated and 50-end-labelled with
[g-32P]-ATP following standard protocols. This was then
phenol/chloroform extracted, ethanol precipitated and
resuspended in 50 ml RNase free water. One microlitre
samples were digested with various concentrations of
RNase A, T1, V1 (Ambion) or S1 nuclease (Invitrogen)
following manufacturers’ protocols. Digestion products
were run on a pre-warmed, 20% (w/v) denaturing
SequaGelTM (National Diagnostics). A radiolabelled
Decade MarkerTM (Ambion) and an alkaline hydrolysis
ladder were also run. Digestion products were imaged by
autoradiography.
Nuclease protection assays
Individual aptamers were labelled and digested with
RNase A or T1 as described above. Samples were also
digested in the presence of a 2–16-fold molar excess of
RHD–CBFb. As previously, digestion products were
run on a 20% (w/v) SequaGelTM and visualized by
autoradiography.
Analytical ultracentrifugation
Samples for analysis by sedimentation velocity were
prepared in 20mM HEPES (pH 6.6), 300mM NaCl,
10mM DTT and 1mM EDTA and were equilibrated for
1 h at room temperature. About 0.42ml samples were
centrifuged in 1.2 cm path-length two-sector aluminium
centrepiece cells, assembled with sapphire windows, in
either an eight-place An-50 Ti or a four-place An-60 Ti
analytical rotor running in an Optima XL-I analytical
ultracentrifuge (Beckman Instruments, Inc., Palo Alto,
California) at 50 000 or 60 000 r.p.m., respectively, at
20C. Changes in solute concentration were detected by
Rayleigh interference and absorbance scans. Samples con-
taining protein and aptamer were measured simultane-
ously at 260 and 280 nm.
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Data analysis
The results were analysed by whole boundary profile
analysis using the program Sedfit v 11.3 (27). Sample
buoyancy parameters, buffer densities and viscosities
were calculated using the program Sednterp (28). The
partial specific volume (v-bar) of proteins was calculated
from amino acid composition using Sednterp (28). For
protein–RNA complexes a weight-average v-bar was
calculated, using a default RNA v-bar of 0.45ml g-1.
For samples in the presence of denaturants the v-bar
was calculated as for a loosely conjugated component,
using Sednterp. The time series of radial absorbance
scans was fitted to the Continuous c(s) model in Sedfit
(27). After optimizing meniscus position and fitting
limits, the best-fit frictional ratio (f/f0) was determined
by iterative least squares fitting. The weight-average
MW of peaks in the s-value distribution was displayed
on the plot and the sedimentation coefficient and MW
values determined by integrating each peak. The MW
determined depends on the buoyancy parameters
calculated, and on the frictional ratio value determined.
Fluorescence anisotropy titrations
The affinities of the minimal RNA aptamers, Apt28A and
Apt45A, their ssDNA equivalents and a dsDNA encom-
passing a RUNX1-binding site was determined using
fluorescence anisotropy. Experiments were performed on
a Spex Fluorolog Tau spectrofluorometer (HORIBA
Jobin Yvon) controlled by Datamax software. The excita-
tion and emission wavelengths were set to 495 and 520 nm,
respectively. Slit widths were set to 5mm and all titrations
were carried out at 20C. The detector integration time
was 5 s and three readings were averaged. Changes in
fluorescence anisotropy were calculated using the
following equation:
r ¼ ðFjj  F?ÞðFjj þ 2F?Þ
where r =fluorescence anisotropy
F||=fluorescence intensity parallel to the
excitation plane
Fr=fluorescence intensity perpendicular to the
excitation plane
The data were fitted to a sigmoidal growth logistic
model using the following equation:
y ¼ A2þ A1A2ð Þ
1þ ðx=x0Þ
 p
where A1 refers to the initial value, A2 refers to the final
value, x0 refers to the mid-point and p is a value relating
to the slope, of the transition. Errors refer the standard
deviation of three titrations. Data fitting was carried out
using OriginPro 7.5 software.
Titrations of RHD–CBFb were into solutions
(160 nM) of RNA or ssDNA oligonucleotides encom-
passing 28A and 45A, or the RUNX1 DNA in 10mM
HEPES, 100mM NaCl pH 7.6 at room temperature.
The RNA aptamer fragments and their DNA equiva-
lents were labelled with fluorescein at their 50-ends.
The RUNX1-binding site was annealed from two
oligonucleotides and was dye labelled on the top strand.
All labelled DNAs were purchased from MWG. During
titrations, the reaction volume did not increase by more
than 5%. Each sample was mixed with a pipette and left
to equilibrate for 15min before data acquisition. The
relative standard error was <4% for all measurements.
The sequences of the labelled oligonucleotides was as
follows:
Apt28A: 50 Fluorescein-AUUACCGGCGAGUUUUGA
ACCGCGUAAU-30
Apt45A: 50 Fluorescein-GGUCCAGGCGCGUUAGCA
AAACCGCGGAUC-30
DNA Apt28A: 50 Fluorescein-ATTACCGGCGAGTTTT
GAACCGCGTAAT-30
DNA Apt45A: 50 Fluorescein-GGTCCAGGCGCGTTA
GCAAAACCGCGGATC-30
RUNX1 top strand: 50 Fluorescein-TTTCCGCCCACAC
AGGCTG-30
RUNX1 bottom strand: 50-CAGCCTGTGTGGGCGGA
AA-30
Unlabelled minimal aptamer sequences Apt28A and
Apt45A were identical except lacking the 50 dye.
RESULTS
Selection and characterization of aptamers against the
RUNX1–CBFb complex
The aptamer selection target was recombinant RUNX1
RHD and its interaction partner CBFb. This protein
dimer has previously been characterized structurally and
its complex with a high-affinity dsDNA oligonucleotide
has been determined (5). The protein was purified from
Escherichia coli as described previously (29) and then
prepared for automated aptamer selection by immobili-
zation on streptavidin-coated microspheres following
brief biotinylation using EZ-link biotin (Pierce), which
modifies lysine side chains (30,31). Western blotting with
anti-biotin antibodies suggested that both components of
the protein dimer were biotinylated (data not shown).
These microspheres were then used as the target for 10
rounds of in vitro RNA aptamer selection with an N50
degenerate library as described in the ‘Materials and
Methods’ section. PCR reactions at the end of various
selection rounds showed increasing amounts of DNA
product. Since these reactions were restricted to 10
cycles to avoid artefacts, they were not saturated so this
result is consistent with recovery of increasing amounts of
anti-target aptamers throughout the SELEX process.
The selected anti-RHD–CBFb aptamer pool was then
tested for its ability to alter sequence-specific DNA
binding by the unmodified RHD–CBFb using EMSAs.
The protein was pre-incubated with the test aptamer
pool before addition of a 32P-labelled ds oligonucleotide
probe encompassing a RUNX1-binding site (11,32). The
mixture was allowed to equilibrate before being separated
on a native polyacrylamide gel. In addition to the selected
pool a number of negative control RNAs were also
assayed. These were the naı¨ve library used for the
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current selections, an individual aptamer from the same
library but selected against the bacterial transcription
factor MetJ (33) or an aptamer pool derived from an
unrelated library and selected against the amyloid
forming protein b2m (30). These controls allowed us to
show that any effects were due to the selected region of the
anti-RHD–CBFb pool, and were independent of the fixed
flanking regions. This aptamer pool caused detectable
inhibition of RHD–CBFb binding to the RUNX1 probe
(Figure 1A), whereas none of the negative controls
showed any effect. In order to confirm that similar
effects would occur with native RUNX1 protein, the
EMSA assay was repeated using nuclear extracts from
Kasumi-1 cells which are known to express RUNX1 (34)
(Figure 1B). The nuclear extract shows a series of retarded
bands, presumably because RUNX1 exists in various
isoforms and can be a component of larger protein
complexes. The presence of RUNX1 in the shifted bands
was confirmed by supershifting the complex with a poly-
clonal antibody directed against the N-terminal region of
RUNX1. The formation of these complexes was com-
pletely ablated by the anti-RHD–CBFb 10th round pool
and unaffected by any of the negative control RNAs, con-
sistent with the idea that the pool inhibits specific DNA
binding by RUNX1. EMSAs were then performed using
radioactively labelled aptamer pool and the recombinant
RHD–CBFb protein. These showed formation of an
RNA–protein complex (data not shown), confirming
that anti-RHD–CBFb aptamers had been selected.
Isolation of high-affinity individual aptamer sequences
In order to isolate individual aptamer sequences that bind
the RHD–CBFb complex with high affinity, aptamer–
protein complexes were isolated from an EMSA gel.
Protein-bound RNAs were eluted, reverse transcribed
into DNA, cloned and sequenced. All sequences between
the expected flanking sequences were 50 nucleotides in
length (Figure 2). The sequences clustered into two
sequence families, each of which contained a single
dominant sequence that was represented 14 and 15
times, respectively. The majority of the remaining
sequences were also closely related, but contained
insertions, deletions or sequence variations. This degree
of sequence identity suggested that each aptamer family
was directed against a single epitope.
A representative aptamer from each family, 28 and 45,
was chosen for further characterization. The affinities of
these individual anti-RHD–CBFb aptamers for their
target were estimated by EMSAs. As shown in Figure 3,
aptamers 28 and 45 bind to RHD–CBFb with apparent
affinities of 100 nM, as judged by the point at which 50%
input RNA was shifted. No binding to the anti-MetJ
aptamer occurred under these conditions (data not
shown). EMSA assays with unmodified versions of
aptamers 28 and 45, i.e. without the 20-fluoro-modified
pyrimidines showed that both versions of the aptamers
have similar affinities for RHD–CBFb (data not shown),
suggesting that these modified nucleotides do not
contribute to binding affinity and/or the structure of the
epitope-binding domain within the aptamer. This is
perhaps a surprising observation but other well charac-
terized aptamers are known with similar properties.
For instance the aptamer that led to MacugenTM was
substantially modified post-selection, to give the final
drug molecule (19). All but two nucleotides of the
original aptamer were modified, without significant effect
on the aptamer-binding properties. To our knowledge this
may be the first instance were aptamer sequences selected
with modified nucleotides are also active in their absence
Figure 1. Aptamers selected against recombinant RHD–CBFb prevent RUNX1 DNA binding. Recombinant RHD–CBFb at the concentration
indicated (A) or 10 mg of total protein from a Kasumi-1 nuclear extract (B) were incubated without (positive control) or with 1mM concentrations
of the following RNAs: the 10th round aptamer pool selected against RHD–CBFb; the naı¨ve pool used in this selection; the anti-b2m pool or the
anti-MetJ aptamer. A 32P-end-labelled RUNX1 dsDNA probe (28) was then added and the sample equilibrated for 15min before electrophoresis.
In (B) when the anti-RUNX1 antibody N20 was added to an identical group of samples at the same time as the aptamers, a proportion of the
retarded species was supershifted. The asterisk indicates the positions of the free DNA probe and the arrowhead indicates the RUNX1 supershift.
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and this may indicate a role for RNA binding by the
RHD–CBFb in vivo.
Although aptamer 28 and 45 transcripts are single
bands on denaturing gels, they migrate on native gels as
a series of discrete bands, suggesting that they have the
ability to equilibrate between several secondary/tertiary
structures. To test which of the possible folds interacted
with RHD–CBFb, their sequences were first analysed
using the program Mfold, which yielded a single
secondary structure prediction for aptamer 45 and three
Aptamer Family 1 
APT1        ----------CTGGTTAT-TAACCGCGTAATAACTTCAACGTCGGAATGTTTCACCTATT--- 
APT2        ---------ACGTGTCTT-CGACCGCGTTATATCTTAATAAAAATCTAGGCCAGTATTGCA-- 
APT5        ----------TGTGTTTC-AAGCCACGTAATCGGTCGTTACTCC------------------- 
APT10       -------TCGTGTTTTAT-TAACCGCGCAATTTGTCTTAAGTCG------------------- 
APT12       ----------CGAGTTTT-GAACCGCGTAATAAAAAAACATTCCTCATTTG------------ 
APT23       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT24       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCTNCANTTG------------ 
APT25       ----------CGAGTTTT-GAACCGCGTAATAAAAA--CATTCCTCATTT------------- 
APT28       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT29       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT30       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT31       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT32       ----------CGAGTTTT-GAACCGNGTAATAAAA---CATTCCTCATTTG------------ 
APT43       -----------TGGTTTT-AAACCACGTACTTCTT---CA-ACCTAGG--------------- 
APT48       ----------CGTGTCATCGA-CCGCGTCATTCACTA--ATTCCGATCCAAAACATTCGTCGT 
APT53       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT55       ----------------NC-CAGGCGCGTTATCAAAAAACCGCGGATNAA-------------- 
APT61       ----------CGCGTTTTCCAACCGCGTAAAACGTCTT-AAGTTTCAT--------------- 
APT81       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT86       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT87       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT89       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT92       ----------CGAGTTTT-GAACCGCGTAATAAAAA--CATTCCTCATTTG------------ 
APT93       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT97       ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT101      ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT103      ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT105      ATTGCAAGTCGTAGTCTT-TGACCGCGCAATCAACTTCGA----------------------- 
APT106      TTGTCATGCGCATGTTTT-TAACCGCGACGGAACTGTAAGATGATTT---------------- 
APT108      ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCCTCATTTG------------ 
APT116      ----------CGAGTTTT-GAACCGCGTAATAAAA---CATTCTCATTTG------------- 
APT119      ---------TGTAGTCTT-CGATCACGTAAATTTGCTTAA----------------------- 
Aptamer Family 2 
APT7        TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT42       TCCAGGCGCGTTAGC--AAAACCGCGGATCGAACTTAGTTGA---------- 
APT45       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT52       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT55       NCCAGGCGCGTTATCAAAAAACCGCGGATNAANCTTAGTTGA---------- 
APT56       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT57       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT66       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT72       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT74       TCCAGGCGCGTTAGC--ANNACCNCGGATCAAACTTAGTTGACAACTAGGAT 
APT78       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT82       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT85       TCCAGGCGCGTTAGC-AAAAACCGCGGATCAAACTTAGTTGA---------- 
APT94       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT95       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
APT96       TCCAGGCGCGTTAGC--AAAACCGCGGATCAAACTTANTTGA---------- 
APT102      TCCAGGCGTGTTAGC--AAAACCGCGGATCAAACTTAGTTGA---------- 
Figure 2. Aptamer sequence alignments and consensus sequences. The random regions of all the sequenced aptamers were aligned using the multiple
alignment program ‘Genebee’ (http://www.genebee.msu.su/services/malign_reduced.html). Of the 58 aptamer sequences, 32 fall into the first family
and 17 into the second. One aptamer (aptamer 55) appears in both. The remaining 10 ‘orphan’ sequences do not match any part of these alignments.
The consensus sequence, generated using the WebLogo program (http://weblogo.berkeley.edu/logo.cgi), is shown below each family.
Nucleic Acids Research, 2009, Vol. 37, No. 20 6823
possible structures for aptamer 28. We then used enzyma-
tic solution structure probing to identify the most likely
solution secondary structure of aptamers without
modified pyrimidines (30) (Figure 4 and Supplementary
Figure S1A and B) and nuclease protection assays to
identify the aptamer residues contacting RHD–CBFb
(Supplementary Figure S1C and D). The resultant
protection profiles demonstrate that the 50 stem-loop
Figure 4. Sequence and secondary structures of representative aptamers. The RNA sequences of aptamers 28 and 45 (A), were analysed using
‘Mfold’. The resultant secondary structures that are most consistent with the enzymatic structure probing (Supplementary Figure S1A and B) are
shown for both aptamers 28 and 45 (B and C, respectively). The selected sequence region is shown in green. Nuclease cleavage sites are indicated by
blue, red, green and yellow arrows, for the C- and U-specific RNase A, the G-specific RNase T1, the single-strand-specific nuclease S1, and ds/
helical-specific nuclease V1, respectively. Regions shown to be protected from nuclease attack by RHD–CBFb are shown in the boxed regions
(Supplementary Figure S1C and D), which includes the conserved secondary structure motif (see Discussion) running from C23–G42 and C29–G50
for aptamers 28 and 45, respectively.
Figure 3. Anti-RHD–CBFb aptamers 28 and 45 bind with high affinity. EMSAs were performed with 32P-labelled aptamers (5000 cpm) incubated
without (first lanes) or with RHD–CBFb at the concentrations shown (A andB). The dotted line on the left indicates the positions of the unbound aptamer.
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structures in both aptamers are likely to be the principal
epitope-binding domains (Figure 4B and C, boxed
regions).
Aptamers and DNA bind to similar sites on the
RUNX1–CBFb complex
In order to determine how aptamers 28 and 45 inhibit
RHD–CBFb DNA binding, a series of competition
experiments between the aptamers and the dsRUNX1
DNA probe were carried out. Figure 5A shows that
both aptamers bound to the RHD–CBFb complex in
the absence of DNA but binding was significantly
reduced in the presence of a molar excess of the
RUNX1 DNA probe. This effect was not seen with
a negative control dsDNA probe containing a binding
site for the transcription factor Oct1 (Oct1 dsDNA).
The converse experiment showed that the specific
32P-labelled-dsDNA probe was incapable of disrupting
the complexes formed between the aptamers and RHD–
CBFb when the aptamers were present in molar excess
(Figure 5B). These results confirm that the pyrimidine-
modified aptamers interfere with formation of DNA–
RHD–CBFb complexes and imply that the protein has
similar affinities for both RNA and dsDNA targets, as
was later confirmed (Figure 7). Similar effects were also
Figure 5. Aptamers 28 and 45 can prevent DNA binding of RUNX1 by binding to similar sites. (A) RHD–CBFb was incubated with either buffer
alone (positive control) or unlabelled dsDNA probes containing RUNX1 or Oct1 consensus-binding sites. 32P-labelled aptamers 28 or 45 (1000 cpm)
were then added and EMSAs performed. The RUNX1 DNAs compete with aptamer binding but the Oct1 sequence does not. (B) RHD–CBFb was
pre-incubated with unlabelled aptamers 28, 45 or buffer (positive control) followed by addition of 32P-end-labelled RUNX1 dsDNA probe (10 000
cpm) followed by EMSAs. Both aptamers compete with binding to the DNA. (C) As in (B), Kasumi-1 or HL60 nuclear extracts were pre-incubated
with unlabelled aptamers 28, 45, the anti-MetJ aptamer or a buffer alone (positive control) followed by addition RUNX1 probe (10 000 cpm) and
EMSA. In some of the experiments a polyclonal antibody against the C-terminal region of RUNX1, C19, was added at the same time as the
aptamers. The asterisk indicates the positions of the free DNA probe and the arrowhead indicates the RUNX1 supershift. Both aptamers compete
with DNA binding by the extracts but the anti-MetJ aptamer does not. (D) RHD–CBFb was incubated with buffer blank (positive control) or
unlabelled aptamers 28, 45 or the anti-MetJ aptamer. The complexes were then challenged by addition of 32P-labelled aptamers 28 or 45 (1000 cpm)
and EMSAs performed. Both aptamers show direct competition as expected, with aptamer 28 having the higher affinity. The positions of unshifted
aptamers in these gels are indicated by the dotted lines.
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seen when unmodified aptamers were used (data not
shown).
In order to confirm these effects on the native RUNX1
protein, competition assays were performed using nuclear
extracts from the RUNX1-expressing cells, Kasumi-1 and
HL60 (Figure 5C). There was clear inhibition of trans-
cription factor complex formation by the individual
aptamers, whereas there was no effect using the anti-
MetJ control aptamer. These data confirm that the
aptamers are able to block binding of the RUNX1
protein to DNA, suggesting that either they bind to a
site that overlaps the DNA-binding domain or somehow
disrupt it. We next tested whether the aptamers bind to
independent sites on the RHD–CBFb complex. Figure 5D
shows that aptamers 28 and 45 compete with each other,
as well as themselves, suggesting that they bind to sites on
the protein complex which are very close to each other if
not identical.
In order to determine whether the RHD–CBFb foot-
prints on aptamers 28 and 45 identified functional,
minimal length RNAs, we assayed unmodified, synthetic
RNA oligonucleotides encompassing the 50 and 30 stem-
loops from each aptamer (Figure 4). Oligonucleotides
‘Apt 28A’ and ‘Apt 45A’ comprise the 50 stem-loops,
which were strongly protected by RHD–CBFb and ‘Apt
28B’ and ‘Apt 45B’ comprise the non-protected 30 stem-
loops (Figure 4 and Supplementary Figure S1C and D).
Figure 6 shows that the 50 stem-loops in each case were as
effective as the full length, modified aptamers in blocking
DNA binding of both purified RHD–CBFb protein and
RUNX1 in nuclear extracts. Incubation with the 30 stem-
loops had no effect and no synergy of inhibition was seen
when they were combined with the 50 stem-loops in the
same reaction. The obvious conclusion is that the 50 stem-
loops of 28 and 30 nts (for aptamers 28 and 45,
respectively), contain all the sequence/structure
information required to bind the RUNX1/RHD–CBFb
proteins.
Aptamers inhibit RHD–CBFb DNA binding by high-affinity
binding to the RHD
The experiments described above are consistent with
the aptamers exerting their effects by binding to the
DNA-binding domain of the RHD–CBFb complex
(Figure 5). However, an additional possibility was that
they could disrupt the interaction between subunits,
which would also lower DNA affinity (35). To examine
these possibilities we analysed the aptamer–RHD–CBFb
protein complexes by sedimentation velocity in an
analytical ultracentrifuge (36). The data (Table 1) show
that the RHD–CBFb dimer remained intact after
biotinylation but was disrupted in the presence of either
Apt28A or Apt45A, which each seemed to make 1 : 1
complexes with one of the two subunits. The resolution
of the sedimentation data was not sufficient to determine
which subunit of the RHD–CBFb dimer was bound.
However, antibodies directed against N- and C-terminal
regions of RUNX1 caused supershifting of the aptamer–
protein complex (Figure 6E), demonstrating that aptamers
bound to the RHD subunit. These results suggest that the
inhibitory action of the aptamers is at least partially due to
disruption of the RHD–CBFb dimer, formation of which
increases DNA affinity by the RHD.
Finally, in order to understand the competition
observed between RNA aptamer and DNA binding, we
determined the equilibrium dissociation constants (Kds)
for RHD–CBFb dimer binding to the RUNX1 dsDNA
probe and Apt28A and Apt45A. To confirm that the
action of the aptamers was RNA specific, rather than a
non-specific effect of adding polynucleotides, we also
assayed ssDNA versions of both minimal aptamer
sequences. Affinities were determined using fluorescence
anisotropy with fluorescein end-labelled oligonucleotides,
as described in the Materials and Methods section. The
results are shown in Figure 7. The anisotropy plots show
binding curves for the dsDNA RUNX1, Apt28A and
Apt45A targets that yield Kds of 95±15; 108±34 and
162±102 nM, respectively. In contrast, the ssDNA
version of Apt28A showed no anisotropy change over
the protein concentration range tested, whilst the
Apt45A equivalent showed a linear increase across this
range, consistent with non-specific binding. These Kd
values are entirely consistent with the competition results
of Figure 5A and B.
DISCUSSION
The experiments described provide novel insights into the
structural and functional features of the RHD–CBFb
complex. The high-affinity RNA aptamers selected
against the RHD–CBFb complex were composed of two
major sequence families that both bind to the RHD
domain of the selection target (Figure 2). RNA
aptamers from both of these sequence families contain a
functional stem-loop with a similar secondary structure,
encompassing a base-paired region interrupted on the 50
leg by a two base bulge (A.G) followed by 3 bp and a
single base insertion (A or C, depending on the aptamer)
(Figure 3). Binding of both aptamers, including the
minimized fragments encompassing just the stem-loop
motifs, occurs to a similar, presumably identical, site on
the RHD. Aptamer–RHD complex formation disrupts the
RHD–CBFb dimer which would be expected to lower its
DNA affinity (Table 1). It is not clear whether the epitope
on RHD bound also overlaps with its DNA-binding
domain, although the efficient ablation of DNA binding
would be consistent with both these effects. There are
multiple examples for transcription factors that use the
same protein domain to specifically bind both RNA and
DNA sequences to regulate gene expression, e.g. Xenopus
laevis TFIIIA, TRA-1, bicoid, p53 and STAT1 (37). X-ray
crystallographic analysis of an RNA–protein complex of a
high-affinity aptamer selected against the NF-kB p50
homodimer revealed that two RNA molecules bind
independently to the p50 N-terminal immunoglobulin-
like domains (24). Each p50 monomer uses the same
surface to recognize the distorted RNA major groove of
the aptamer as is observed in the NF-kB DNA/p50
complex. Interestingly, the nucleic acid binding interfaces
of p53, STAT1, NF-kB and RUNX1 are strikingly similar
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Figure 6. The 50 stem-loops of aptamers 28 and 45 bind to the RHD of RUNX1 to block DNA binding. (A) and (B) RHD–CBFb was incubated
with 2.5 mM unlabelled aptamers 28 or 45, the anti-MetJ aptamer or buffer alone (positive control), or the minimal aptamer fragments Apt28A,
Apt45A, Apt28B or Apt45B and then 32P-labelled RUNX1 dsDNA probe (10 000 cpm) added and EMSAs performed. The full length aptamers as
well as the ‘A’ fragments, but not the anti-MetJ aptamer or ‘B’ fragments, were equally effective at competing with binding to the RUNX1 probe. (C)
and (D) nuclear extracts from Kasumi-1 or HL60 cells were pre-incubated with the putative minimal aptamer fragments Apt28A and Apt28B or
Apt45A and Apt45B prior to challenge with RUNX1 probe, as in (A). Only the ‘A’ fragments show inhibition of DNA binding. (E) In order to
identify which subunit within the RHD–CBFb dimer the minimal aptamer fragments bind, 32P-end-labelled Apt28A and Apt45A were incubated
with Kasumi-1 nuclear extracts (positive control) and complexes were supershifted with antibodies N20 or C19. The retarded minimal aptamer
species supershift with both antibodies confirming the presence of RHD in the aptamer complexes. A similar EMSA with RUNX1 dsDNA is shown
alongside to confirm the activity of the antibodies used. Asterisks indicate the positions of free oligonucleotides and the arrowheads the positions of
the RUNX1 supershifts.
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(37). The DNA-binding domains of these proteins belong
to the p53 family of transcription factors that share a
common DNA-binding immunoglobulin fold. Although
speculative, this raises the possibility that specific cellular
RNAs may target RUNX1 to mediate a further level of
regulatory control. The idea that there might be dual roles
for transcription factors in RNA and DNA binding has
been reinforced recently by the observation that ribosomal
protein Rps3 is an RNA-binding KH domain component
in NF-kB complexes that mediates selective gene
regulation (38).
Given these precedents and the fact that the RNA
aptamers described here efficiently compete with the
cognate RUNX1 DNA in vitro, it seems reasonable to
suggest that the aptamer is binding the p53-like immuno-
globulin fold DNA-binding domain of the RHD. One
hypothesis is that the RNA aptamers could act as mole-
cular DNA mimics, adopting three-dimensional structures
with similar physico-chemical properties to cognate
RHD DNA. However, the aptamers lack extended base-
paired matches to the RUNX1 DNA consensus and only
function as ribo-oligonucleotides (Figure 7). This suggests
that they are novel recognition partners with the ability to
both bind RHD and displace the CBFb subunit.
Experiments performed by others demonstrated that the
binding of small molecular weight compounds sharing a
common structural feature, namely a 2-aminothiazole
attached to an aromatic ring, can cause disruption of the
RHD–CBFb complex (39). These potential drugs bind to
a site on the CBFb subunit that is displaced from the
interface with RUNX1 DNA. Our data suggest that we
have isolated aptamer inhibitors with a different mode
of action, i.e. with a primary binding target located on
the RHD domain and a significantly higher affinity
(Kd 100 nM versus >10 mM) than the small molecular
weight ligands. One possibility is that the aptamers bind
to the RHD DNA-binding motif in such a way that they
stabilize its low-affinity conformation for CBFb, a type of
negative RNA allostery. Whilst our experiments have
Table 1. Sedimentation velocity analysis of aptamer/RHD-CBFb complex formation
Sample Concentration Expected Mass (Da) Observed Sed
Vel Massa (Da)
Comment
RHD–CBFb 250 nM 32 514 36 000
Biotinylated RHD–CBFb 250 nM 32 514b 35 600 Biotinylation does not disrupt
the protein dimer
Apt28A 500 nM 8939 7600
Apt28B 500 nM 9150 10 000
Apt45A 500 nM 9665 10 600
Apt45B 500 nM 5411 Not done
RHD–CBFb+Apt28A Protein 250 nM (RHD–CBFb):Apt28A=41 453
(RHD):Apt28A=25 660
(CBFb):Apt28A=24 732
Single peak at 23 300c There is no evidence that the
Apt28A binds to the
dimeric target, rather it is
making a 1 : 1 complex with
one of the monomers
Aptamer 500 nM
RHD–CBFb+Apt28B Protein 250 nM (RHD–CBFb):Apt28B=41 664
(RHD):Apt28B=25 871
(CBFb):Apt28B=24 943
Peaks at 33 000 and 9000 Apt28B does not appear to
bind to the proteinAptamer 500 nM
RHD–CBFb+Apt45A Protein 250 nM (RHD–CBFb):Apt45A=42 179
(RHD):Apt45A=26 386
(CBFb):Apt45A=25 458
Single peak at 25 000c There is no evidence that the
Apt45A binds to the dimeric
target, rather it is making a
1 : 1 complex with one of the
monomers
Aptamer 500 nM
RHD–CBFb+Apt45B Protein 250 nM (RHD–CBFb):Apt45B=37 925
(RHD):Apt45B=22 132
(CBFb):Apt45B=21 204
Peaks at 31 100 and 5500 Apt45B does not appear to
bind to the proteinAptamer 500 nM
a±10%.
bPlus mass of EZ-link.
cBroad peak at higher s values was also present, consistent with aggregating material.
Figure 7. Affinities of the minimal aptamer domains and dsDNA
RUNX1 probe for RHD–CBFb. Plots of fluorescence anisotropy
versus RHD–CBFb concentration are shown for titrations against
Apt28A, Apt45A and their equivalent ssDNAs, as well as the
dsDNA RUNX1 probe (inset). Curves represent fits to the binding
data, as described in the text. Anisotropy and solution conditions,
including the sequences of the oligonucleotides are described in
‘Materials and Methods’ section.
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uncovered a novel effect of oligonucleotide binding to
RHD, understanding the consequences for the CBFb
interaction can only be resolved by structural studies of
the aptamer–RHD complexes and these are underway.
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